MCID: LMY014
MIFTS: 53

Leiomyoma, Uterine

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Leiomyoma, Uterine

MalaCards integrated aliases for Leiomyoma, Uterine:

Name: Leiomyoma, Uterine 57 40
Uterine Leiomyoma 12 37 29 55 6
Uterine Fibroids 43 63 73
Leiomyoma, Uterine, Somatic 57 13
Plexiform Leiomyoma 12 73
Uterine Fibroid 12 15
Leiomyoma of Corpus Uteri 12
Uterus Fibroma 12
Ul 57

Characteristics:

OMIM:

57
Inheritance:
somatic mutation

Miscellaneous:
uterine leiomyomata are found in hereditary leiomyomatosis and renal cell cancer syndrome


HPO:

32
leiomyoma, uterine:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:



External Ids:

OMIM 57 150699
Disease Ontology 12 DOID:13223
ICD10 33 D25 D25.9
ICD9CM 35 218 218.9
MeSH 44 D007889
NCIt 50 C3434
MedGen 42 C0042133
KEGG 37 H01640
SNOMED-CT via HPO 69 263681008 124975008

Summaries for Leiomyoma, Uterine

MedlinePlus : 43 Uterine fibroids are the most common benign tumors in women of childbearing age. Fibroids are made of muscle cells and other tissues that grow in and around the wall of the uterus, or womb. The cause of fibroids is unknown. Risk factors include being African American or being overweight. Many women with fibroids have no symptoms. If you do have symptoms, they may include Heavy or painful periods or bleeding between periods Feeling "full" in the lower abdomen Urinating often Pain during sex Lower back pain Reproductive problems, such as infertility, multiple miscarriages or early labor Your health care provider may find fibroids during a gynecological exam or by using imaging tests. Treatment includes drugs that can slow or stop their growth, or surgery. If you have no symptoms, you may not even need treatment. Many women with fibroids can get pregnant naturally. For those who cannot, infertility treatments may help. NIH: National Institute of Child Health and Human Development

MalaCards based summary : Leiomyoma, Uterine, also known as uterine leiomyoma, is related to kidney cancer and submucous uterine fibroid, and has symptoms including pelvic pain An important gene associated with Leiomyoma, Uterine is MIRLET7C (MicroRNA Let-7c
exogenous Let-7 microRNAs could directly repress the dominant transcript of HMGA2.Let-7 repression of HMGA2 inhibited cellular proliferation.), and among its related pathways/superpathways are MicroRNAs in cancer and Cell Differentiation - Index. The drugs Desogestrel and Dienogest have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and testes, and related phenotype is uterine leiomyoma.

Disease Ontology : 12 A uterine benign neoplasm derived from the smooth muscle layer of the uterus.

PubMed Health : 63 About uterine fibroids: Many women have benign (non-cancerous) growths known as fibroids in or on their womb (uterus). Most fibroids are small and don't cause any problems. They are usually discovered by chance. Depending on where fibroids are located, they may cause period pain, heavy menstrual bleeding or other symptoms.There are different ways to treat fibroids. The most suitable treatment will greatly depend on a woman’s individual circumstances – such as whether she would still like to have children.Fibroids are made up of muscle cells and connective tissue. Their size, shape and location vary. Fibroids are mainly categorized based on where they are:

Wikipedia : 76 Uterine fibroids, also known as uterine leiomyomas or fibroids, are benign smooth muscle tumors of the... more...

Description from OMIM: 150699

Related Diseases for Leiomyoma, Uterine

Diseases related to Leiomyoma, Uterine via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
# Related Disease Score Top Affiliating Genes
1 kidney cancer 29.8 MIR150 MIR21 MIR29C
2 submucous uterine fibroid 12.2
3 subserous uterine fibroid 12.2
4 hereditary leiomyomatosis and renal cell cancer 12.1
5 blood group--ul system 12.0
6 uterine corpus bizarre leiomyoma 11.2
7 renal cell carcinoma, papillary, 1 11.1
8 uterine corpus epithelioid leiomyoma 11.0
9 uterine corpus dissecting leiomyoma 11.0
10 uterine corpus myxoid leiomyoma 11.0
11 uterine corpus apoplectic leiomyoma 11.0
12 uterine corpus cellular leiomyoma 11.0
13 miyoshi muscular dystrophy 1 10.7 MIR335 MIR34A
14 uterine benign neoplasm 10.6 FH HMGA2
15 reproductive organ benign neoplasm 10.6 FH HMGA2
16 dermatomyositis 10.5 MIR21 MIR34A
17 facioscapulohumeral muscular dystrophy 1 10.4 MIR21 MIR335 MIR34A
18 thyroid cancer, nonmedullary, 1 10.3 MIR21 MIR29C MIR34A
19 inclusion body myositis 10.3 MIR197 MIR21 MIR34A
20 leiomyoma 10.3
21 ovarian epithelial cancer 10.2 MIR376B MIR377
22 leukemia, acute myeloid 10.1 MIR21 MIR335 MIR451A MIRLET7C
23 nonalcoholic fatty liver disease 10.1 MIR203A MIR29C MIR34A MIR451A MIRLET7C
24 leiomyosarcoma 10.1
25 endometriosis 10.1 MIR150 MIR196B MIR29C
26 pituitary adenoma 10.1 MIR197 MIR212
27 laryngotracheitis 10.1
28 oral squamous cell carcinoma 10.0 MIR197 MIR203A MIR21 MIR34A
29 smooth muscle tumor 10.0
30 muscular dystrophy, duchenne type 10.0 MIR197 MIR29C MIR335 MIR34A MIR486-1
31 erythema multiforme 9.9
32 corneal neovascularization 9.9
33 herpes simplex 9.9
34 primary biliary cirrhosis 9.9 MIR150 MIR197 MIR212 MIR451A
35 glioblastoma 9.9 MIR197 MIR21 MIR34A MIR451A MIR486-1
36 leukemia, chronic lymphocytic 9.8 MIR150 MIR21 MIR29C MIR34A
37 leiomyoma cutis 9.7
38 uterine inversion 9.7
39 uterine sarcoma 9.7
40 leukemia, acute lymphoblastic 9.5 MIR196B MIR203A MIR21 MIR335 MIR451A MIRLET7C
41 pancreatic cancer 9.5 MIR203A MIR21 MIR212 MIR32 MIR34A
42 pancreatic ductal adenocarcinoma 9.4 MIR150 MIR196B MIR203A MIR21 MIR29C
43 gastric cancer 9.2 MIR150 MIR196B MIR203A MIR21 MIR34A MIR451A
44 hepatocellular carcinoma 9.1 MIR150 MIR203A MIR21 MIR212 MIR34A MIRLET7C
45 lung cancer 7.5 MIR150 MIR197 MIR203A MIR21 MIR212 MIR29C

Graphical network of the top 20 diseases related to Leiomyoma, Uterine:



Diseases related to Leiomyoma, Uterine

Symptoms & Phenotypes for Leiomyoma, Uterine

Symptoms via clinical synopsis from OMIM:

57
Genitourinary Internal Genitalia Female:
uterine leiomyomas, benign


Clinical features from OMIM:

150699

Human phenotypes related to Leiomyoma, Uterine:

32
# Description HPO Frequency HPO Source Accession
1 uterine leiomyoma 32 HP:0000131

UMLS symptoms related to Leiomyoma, Uterine:


pelvic pain

Drugs & Therapeutics for Leiomyoma, Uterine

PubMedHealth treatment related to Leiomyoma, Uterine: 63

Fibroids usually only need to be treated if they are causing fertility problems or could cause problems during pregnancy. The choice of treatment will mainly depend on whether a woman would still like to have children – and how she sees the advantages and disadvantages of the various treatments. The severity of the symptoms and the size and position of the fibroids may also determine which treatments are an option.There is no rush to make a treatment decision. Fibroids usually grow very slowly. So you can take your time to read up on all of the pros and cons of the different treatments. Sometimes it is also a good idea to get several opinions from different doctors.The treatment goals may include the following:Reduce menstrual bleedingRelieve pain, cramps and tensionHelp with difficulties emptying the bladder and digestionPreserve or improve fertilityThe treatment options include:Hormone therapies: The main hormone therapies are hormonal contraceptives to reduce heavy menstrual bleeding, and hormones that prevent the production of estrogens (GnRH analogues).Surgical removal of the fibroid or the entire womb.Closing off the blood vessels that supply the fibroid with blood (uterine fibroid embolization). The aim is to shrink the fibroids.Other procedures like focused ultrasound surgery (FUS). This is a relatively new procedure, and its advantages and disadvantages have not yet been fully studied. FUS uses high-intensity ultrasound waves to heat and destroy the fibroid.Other treatments like painkillers, herbal remedies or acupuncture.NSAID (non-steroidal anti-inflammatory drug) painkillers like ibuprofen or diclofenac have been proven to relieve period pain. But there are no studies that have specifically looked into the effects of NSAIDs in women with fibroids. This is also true for acupuncture. Some herbal remedies have been studied more than others, but there's currently no evidence that they are effective in treating fibroids.

Drugs for Leiomyoma, Uterine (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 259)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Desogestrel Approved Phase 4 54024-22-5 40973
2
Dienogest Approved Phase 4 65928-58-7
3
Goserelin Approved Phase 4,Phase 3,Phase 2 65807-02-5 47725 5311128
4
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
5
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
6
Dimenhydrinate Approved Phase 4 523-87-5 441281
7
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
8
Misoprostol Approved Phase 4,Phase 3,Phase 2 59122-46-2 5282381
9
Calcium Carbonate Approved, Investigational Phase 4,Phase 3 471-34-1
10
Leuprolide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53714-56-0 3911 657181
11
Tranexamic Acid Approved Phase 4,Phase 3,Phase 1 1197-18-8 5526
12
Anastrozole Approved, Investigational Phase 4,Phase 3 120511-73-1 2187
13
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
14
Zinc Approved, Investigational Phase 4 7440-66-6 23994
15
Zinc oxide Approved Phase 4 1314-13-2
16
Letrozole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 112809-51-5 3902
17
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
18
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
19
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
20
Acetaminophen Approved Phase 4 103-90-2 1983
21
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
22
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
23
Morphine Approved, Investigational Phase 4 57-27-2 5288826
24
Prilocaine Approved Phase 4 721-50-6 4906
25
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
26
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
27
Dinoprostone Approved Phase 4,Not Applicable 363-24-6 5280360
28
Mifepristone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 84371-65-3 55245
29
Levonorgestrel Approved, Investigational Phase 4,Phase 2,Not Applicable 797-63-7, 17489-40-6 13109
30
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 57-83-0 5994
31
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
32
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Not Applicable 50-02-2 5743
33
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
34
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
35
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
36
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
37
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 56-40-6 750
38
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
39
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
41
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
42
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
43
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
44
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
45
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
46
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
47
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
48
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
49
Tocopherol Approved, Investigational, Nutraceutical Phase 4 1406-66-2 14986
50
Vitamin C Approved, Nutraceutical Phase 4,Phase 3 50-81-7 5785 54670067

Interventional clinical trials:

(show top 50) (show all 350)
# Name Status NCT ID Phase Drugs
1 Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
2 High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Unknown status NCT01239641 Phase 4
3 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
4 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
5 Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy Unknown status NCT01632202 Phase 4
6 Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy Unknown status NCT02643186 Phase 4 preoperative vaginal misoprostol
7 Fibroids in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
8 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
9 Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
10 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
11 The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids. Completed NCT00995878 Phase 4
12 Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids Completed NCT00159328 Phase 4
13 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
14 Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future Completed NCT00180739 Phase 4
15 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
16 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
17 Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery Completed NCT01388907 Phase 4
18 Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial Completed NCT01393704 Phase 4 Vasopressin
19 Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx) Completed NCT02286063 Phase 4 Ambulatory Oxygen
20 Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
21 Comparing Two Types of Sedation to Gynaecological Patients Completed NCT01412632 Phase 4 Remifentanil, propofol and citanest
22 Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy Completed NCT02154932 Phase 4 2 doses 400 microgram misoprostol;single dose misoprostol
23 Impact of Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
24 Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas Recruiting NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
25 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Recruiting NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
26 A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy Recruiting NCT03210324 Phase 4 Mifepristone tablets
27 Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Recruiting NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
28 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
29 Misoprostol for Reduction of Blood Loss During Fibroid Surgery Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
30 Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
31 Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation Recruiting NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
32 Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy Recruiting NCT02288130 Phase 4 GnRHa;Ulipristal
33 The Effect of Ulipristal Acetate (UPA) on Women Ovarian Reserve Recruiting NCT02361892 Phase 4 ulipristal acetate
34 Ulipristal Use in Chinese Population Active, not recruiting NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
35 Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery Enrolling by invitation NCT02812186 Phase 4 Rocuronium
36 Preemptive Analgesia Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
37 Peritoneal Cavity Conditioning Decreases Pain, Inflammation and Adhesions Terminated NCT01344486 Phase 4
38 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
39 Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids Unknown status NCT02189083 Phase 3 TSD
40 Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy Unknown status NCT01280045 Phase 3
41 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
42 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
43 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
44 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
45 3D Sonohysterography vs Hysteroscopy: Study for the Evaluation of Intrauterine Abnormalities Unknown status NCT02682433 Phase 3
46 Understanding Experimentally Induced Hot Flushes Unknown status NCT00455689 Phase 2, Phase 3 Leuprolide acetate (Lupron)
47 Intravenous Tranexamic Acid Versus Pericervical Tourniquet To Decrease Blood Loss In Trans-Abdominal Myomectomy Unknown status NCT02733952 Phase 3 Tranexamic Acid
48 Therapeutic MRI Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids Completed NCT01141062 Phase 3
49 Therapeutic MRI-HIFU Ablation of Uterine Fibroids in a 3T MRI Scanner Completed NCT01064960 Phase 3
50 Mifepristone for Treatment of Uterine Fibroids Completed NCT00712595 Phase 2, Phase 3 Mifepristone;Mifepristone

Search NIH Clinical Center for Leiomyoma, Uterine

Genetic Tests for Leiomyoma, Uterine

Genetic tests related to Leiomyoma, Uterine:

# Genetic test Affiliating Genes
1 Uterine Leiomyoma 29 HMGA2

Anatomical Context for Leiomyoma, Uterine

MalaCards organs/tissues related to Leiomyoma, Uterine:

41
Uterus, Smooth Muscle, Testes, Prostate, Bone, Endothelial, Lung

Publications for Leiomyoma, Uterine

Articles related to Leiomyoma, Uterine:

(show top 50) (show all 629)
# Title Authors Year
1
The effect of TGF-I^ signaling on regulating proliferation of uterine leiomyoma cell via ERI+ signaling activated by bisphenol A, octylphenol and nonylphenol <i>in vitro</i>. ( 29970676 )
2018
2
Placenta increta after high intensity-focused ultrasound for the treatment of a uterine leiomyoma. ( 29410151 )
2018
3
Deep sequencing reveals the molecular pathology characteristics between primary uterine leiomyoma and pulmonary benign metastasizing leiomyoma. ( 29484624 )
2018
4
The AKT/BCL-2 axis mediates survival of uterine leiomyoma in a novel 3D spheroid model. ( 29381777 )
2018
5
Clinical Predictors of Successful Vaginal Myomectomy for Prolapsed Pedunculated Uterine Leiomyoma. ( 29449196 )
2018
6
Establishment of a novel mouse xenograft model of human uterine leiomyoma. ( 29891843 )
2018
7
Association of Uterine Leiomyomas With Central Centrifugal Cicatricial Alopecia. ( 29282458 )
2018
8
Association between fok1 polymorphism of vitamin D receptor gene with uterine leiomyoma in Turkish populations. ( 29391329 )
2018
9
Increased Risk of Venous Thromboembolism in Women with Uterine Leiomyoma: A Nationwide, Population-Based Case-Control Study. ( 29375226 )
2018
10
Spontaneous pregnancy during ulipristal acetate treatment of giant uterine leiomyoma. ( 28730656 )
2018
11
What MRI features suspect malignant pure mesenchymal uterine tumors rather than uterine leiomyoma with cystic degeneration? ( 29400019 )
2018
12
Peritoneal sarcomatosis 5 years after laparoscopic morcellation of uterine leiomyoma. ( 29338993 )
2018
13
Successful operative treatment of uterine leiomyoma with extensive intravenous extension to the IVC, right heart, and pulmonary arteries. ( 29338669 )
2018
14
Overexpression of the 14-3-3I^ protein in uterine leiomyoma cells results in growth retardation and increased apoptosis. ( 29382566 )
2018
15
Comment on: Delayed intestinal perforation and vertebral osteomyelitis after high-intensity focused ultrasound treatment for uterine leiomyoma. ( 29569640 )
2018
16
Malignant transformation of uterine leiomyoma to myxoid leiomyosarcoma after morcellation associated with <i>ALK</i> rearrangement and loss of 14q. ( 29963223 )
2018
17
Paracrine Pathways in Uterine Leiomyoma Stem Cells Involve Insulinlike Growth Factor 2 and Insulin Receptor A. ( 28324020 )
2017
18
Aspirin inhibits the proliferation of human uterine leiomyoma cells by downregulation of Ka89Rasa89p110I+ interaction. ( 28849118 )
2017
19
Replication of GWAS loci revealed the moderate effect of TNRC6B locus on susceptibility of Saudi women to develop uterine leiomyomas. ( 27987337 )
2017
20
InA vitro effects of phthalate esters in human myometrial and leiomyoma cells and increased urinary level of phthalate metabolite in women with uterine leiomyoma. ( 28292620 )
2017
21
Novel Fumarate Hydratase Mutation in Siblings With Early Onset Uterine Leiomyomas and Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome. ( 28700432 )
2017
22
A large uterine leiomyoma leading to non-puerperal uterine inversion: A case report. ( 28280801 )
2017
23
Association between urinary phthalate metabolites and risk of breast cancer and uterine leiomyoma. ( 28951174 )
2017
24
Versican Proteolysis by ADAMTS Proteases and Its Influence on Sex Steroid Receptor Expression in Uterine Leiomyoma. ( 28323982 )
2017
25
Delayed intestinal perforation and vertebral osteomyelitis after high-intensity focused ultrasound treatment for uterine leiomyoma. ( 28989929 )
2017
26
Differential DNA Hydroxymethylation in Human Uterine Leiomyoma Cells Depending on the Phase of Menstrual Cycle and Presence of MED12 Gene Mutations. ( 28944423 )
2017
27
Metastases of breast cancer to a uterine leiomyoma. ( 28925535 )
2017
28
The effect of uterine leiomyoma on the risk of malpresentation and cesarean: a meta-analysis. ( 28027686 )
2017
29
Highly heterogeneous genomic landscape of uterine leiomyomas byA whole exome sequencing and genome-wide arrays. ( 27889101 )
2017
30
Catechol-O-methyltransferase Val158Met polymorphism is associated with increased risk of multiple uterine leiomyomas either positive or negative for MED12 exon 2 mutations. ( 27491313 )
2017
31
Non-neural granular cell tumor of the uterine corpus mimicking uterine leiomyoma: A case report. ( 28781812 )
2017
32
Primary, non-germinal center, double-expressor diffuse large B cell lymphoma confined to a uterine leiomyoma: A case report. ( 29159259 )
2017
33
A Role for Progesterone-Regulated sFRP4 Expression in Uterine Leiomyomas. ( 28637297 )
2017
34
Berberine Inhibits Uterine Leiomyoma Cell Proliferation via Downregulation of Cyclooxygenase 2 and Pituitary Tumor-Transforming Gene 1. ( 27799459 )
2017
35
Atypical uterine leiomyoma: a case report and review of the literature. ( 26801982 )
2016
36
Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings. ( 26574848 )
2016
37
EP32.06: Study of contrast-enhanced ultrasound in evaluating clinical therapeutic response with high intensity focused ultrasound for uterine leiomyoma and follow-up result. ( 27647516 )
2016
38
Genetic variability within Adenosine Deaminase gene and uterine leiomyomas. ( 26918693 )
2016
39
Comment on &amp;quot;Laparoscopic Myomectomy of a Symptomatic Uterine Leiomyoma in a 15-Year-Old Adolescent&amp;quot;. ( 27965124 )
2016
40
G-protein-coupled estrogen receptor-30 gene polymorphisms are associated with uterine leiomyoma risk. ( 26773178 )
2016
41
PI3K/Akt/mTOR signaling &amp;amp; its regulator tumour suppressor genes PTEN &amp;amp; LKB1 in human uterine leiomyomas. ( 27748285 )
2016
42
MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas. ( 27187686 )
2016
43
A subserosal, pedunculated, multilocular uterine leiomyoma with ovarian tumor-like morphology and histological architecture of adenomatoid tumors: a case report and review of the literature. ( 27998309 )
2016
44
Down-regulation and gene hypermethylation of the 14-3-3 gamma in uterine leiomyoma. ( 27100507 )
2016
45
Serum YKL-40 Level Positively Correlates With Uterine Leiomyomas. ( 27170664 )
2016
46
Impact of null genotypes of GSTT1 and GSTM1 with uterine leiomyoma risk in Iranian population. ( 26785830 )
2016
47
Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 expression and regulation in uterine leiomyoma. ( 26702771 )
2016
48
Primary Human Uterine Leiomyoma Cell Culture Quality Control: Some Properties of Myometrial Cells Cultured under Serum Deprivation Conditions in the Presence of Ovarian Steroids. ( 27391384 )
2016
49
The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development. ( 25922306 )
2016
50
MicroRNA-15b regulates reversion-inducing cysteine-rich protein with Kazal motifs (RECK) expression in human uterine leiomyoma. ( 27530410 )
2016

Variations for Leiomyoma, Uterine

ClinVar genetic disease variations for Leiomyoma, Uterine:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 FH NM_000143.3(FH): c.322C> T (p.Gln108Ter) single nucleotide variant Pathogenic/Likely pathogenic rs1060499630 GRCh37 Chromosome 1, 241676959: 241676959
2 FH NM_000143.3(FH): c.322C> T (p.Gln108Ter) single nucleotide variant Pathogenic/Likely pathogenic rs1060499630 GRCh38 Chromosome 1, 241513659: 241513659
3 PTCH1 NM_001083603.2(PTCH1): c.109del (p.Cys37Valfs) deletion Uncertain significance GRCh38 Chromosome 9, 95516712: 95516712
4 PTCH1 NM_001083603.2(PTCH1): c.109del (p.Cys37Valfs) deletion Uncertain significance GRCh37 Chromosome 9, 98278994: 98278994

Copy number variations for Leiomyoma, Uterine from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 70739 12 64503703 64646338 Duplication HMGA2 Uterine leiomyoma
2 230938 8 100959547 100975071 Translate COX6C Uterine leiomyoma

Expression for Leiomyoma, Uterine

Search GEO for disease gene expression data for Leiomyoma, Uterine.

Pathways for Leiomyoma, Uterine

Pathways related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.8 HMGA2 MIR150 MIR203A MIR21 MIR29C MIR32
2 10.74 MIR150 MIR203A
3 10.4 MIR29C MIRLET7C

GO Terms for Leiomyoma, Uterine

Cellular components related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 MIR150 MIR197 MIR21 MIR212 MIR29C MIR323A

Biological processes related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell migration GO:0030336 9.54 MIR21 MIR29C MIR34A
2 negative regulation of sprouting angiogenesis GO:1903671 9.48 MIR34A MIR377
3 positive regulation of cell cycle arrest GO:0071158 9.46 HMGA2 MIR34A
4 negative regulation of vascular endothelial cell proliferation GO:1905563 9.43 MIR29C MIR34A
5 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.4 MIR21 MIR451A
6 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.32 MIR21 MIR34A
7 positive regulation of endothelial cell differentiation GO:0045603 9.26 MIR150 MIR21
8 negative regulation of angiogenesis GO:0016525 9.26 MIR21 MIR212 MIR29C MIR34A
9 gene silencing by miRNA GO:0035195 9.23 MIR150 MIR21 MIR212 MIR29C MIR32 MIR34A
10 positive regulation of cellular senescence GO:2000774 9.16 HMGA2 MIR34A

Molecular functions related to Leiomyoma, Uterine according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR150 MIR21 MIR212 MIR29C MIR32 MIR34A

Sources for Leiomyoma, Uterine

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....